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Systemic treatment for psoriasis and malignancies: A real risk?
Dear Editor,
We read with great interest the recent article by Magnano et al. (2017)
which showed that the risk of malignancy seemed not to be increased
in their cohort of psoriatic patients treated with biologic drugs. Since
long term effects of biologic drugs, especially on malignancy risk, is still
a major matter of debate, we conducted a 12-year retrospective study
(January 2005 to February 2017) investigating the development of
malignancies in psoriasis patients attending the Dermatological Clinic
of the University Federico II of Naples undergoing conventional or bio-
logic systemic treatment. The study population consisted of 915
patients (mean age 58.7 years, 495 male and 420 female) affected by
moderate to severe psoriasis: 534 treated with biologics, 352 with tra-
ditional systemic drug, and 29 with narrowband (nb)-UVB photother-
apy. The average treatment time was 31.5 months (37.2 months for
biologics and 26.6 years for conventional systemic drugs). We detected
8 cases of solid malignancies (6 male and 2 female, mean age 61 years),
4 during biologic therapy, 3 under methotrexate treatment, and
1 during nb-UVB phototherapy (Table 1). No case of hematological
malignancy was observed. Mean treatment duration at tumor diagnosis
was 43.6 months. Particularly, mean treatment duration at tumor diag-
nosis between conventional systemic drugs (49.7 months) and biologics
(44.3 months) was comparable. Our results are in line with those of
Magnano et al. (2017), showing that biologic treatment seemed not to
increase malignancy risk in psoriasis patients. The frequency of malig-
nancy was comparable between subjects treated with biologics or con-
ventional drugs. However, it should be stated that most of the patients
treated with biologics underwent prior conventional systemic treat-
ment, possibly influencing our results. Very recent literature data
reported that patients with psoriasis may experience an elevated risk
of melanoma and hematologic cancers (Reddy, Martires, & Wu, 2017),
non-melanoma skin cancer (Wilton, Crowson, & Matteson, 2016), and
lung cancer (Chiesa Fuxench, Shin, Ogdie Beatty, & Gelfand, 2016).
The risk seemed not to be increased by conventional systemic or bio-
logic therapies (Reddy et al., 2017). We did not identify any case of
TABLE 1 Patients developing a malignancy during systemic treatment for psoriasis
Patient Sex Age
Previous
therapies Therapy Dosage Tumor
Time between
beginning of the
therapy and diagnosis
of tumor (months) Comorbidities
1 M 53 Nb-UVB
therapy
Acitretin
Cyclosporine
Methotrexate 7.5 mg weekly Cholangiocarcinoma 52 None
2 M 62 Cyclosporine
Methotrexate
Infliximab
Etanercept 50 mg weekly Squamous cell
carcinoma of the
penis
72 Psoriatic arthritis,
diabetes, hypertension,
dyslipidemia
3 M 73 Nb-UVB
Acitretin
Cyclosporine
Ustekinumab 45 mg every
12 weeks
Lung cancer 31 Hypertension
4 M 71 Cyclosporine Nb-UVB 2 times a week Liver cancer 42 Hepatitis C
5 F 42 NB-UVB
Cyclosporine
Adalimumab 40 mg every
2 weeks
Thyroid cancer 25 None
6 M 72 NB-UVB
Cyclosporine
Efalizumab
Etanercept
Adalimumab
Methotrexate 7.5 mg weekly Bladder cancer 34 None
7 M 41 Cyclosporine Adalimumab 40 mg every
2 weeks
Thyroid cancer 49 Psoriatic arthritis,
hypertension,
dyslipidemia
8 F 74 Etanercept
Adalimumab
Methotrexate 7.5 mg weekly Renal cell carcinoma 71 Psoriatic arthritis
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melanoma or hematologic cancers among our cohort of psoriasis
patients. Moreover, the number of detected solid neoplasia was limited
(8/915), and the mean age of these subjects was also high (mean age
61 years) which is itself considered one of the most important risk fac-
tors for carcinogenesis. Indeed, it should be always kept in mind other
well-known risk factor for cancerous disease such as high mean age,
longtime previous treatment with other immunosuppressant agents
and long duration of the disease (Zarur, D’almeida, Mafort, Gusmao, &
Avelleira, 2014). In conclusions, our study confirmed the results of
Magnano et al. (2017), enriching the data on a 12-year retrospective
observation on over 900 patients, suggesting that biologic drugs did
not seem to increase the risk for malignancies in psoriasis subjects.
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